sr 27897 has been researched along with cyclic gmp in 1 studies
| Studies (sr 27897) | Trials (sr 27897) | Recent Studies (post-2010) (sr 27897) | Studies (cyclic gmp) | Trials (cyclic gmp) | Recent Studies (post-2010) (cyclic gmp) |
|---|---|---|---|---|---|
| 48 | 3 | 16 | 22,346 | 333 | 4,062 |
| Protein | Taxonomy | sr 27897 (IC50) | cyclic gmp (IC50) |
|---|---|---|---|
| Phosphodiesterase | Bos taurus (cattle) | 0.1 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | 2.4 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | 2.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arnone, M; Gonalons, N; Gueudet, C; Gully, D; Heaulme, M; Keane, P; Le Fur, G; Poncelet, M; Santucci, V; Thurneyssen, O | 1 |
1 other study(ies) available for sr 27897 and cyclic gmp
| Article | Year |
|---|---|
Neurobehavioural effects of SR 27897, a selective cholecystokinin type A (CCK-A) receptor antagonist.
Topics: Animals; Apomorphine; Brain; Cyclic GMP; Dose-Response Relationship, Drug; Female; Indoleacetic Acids; Male; Mice; Motor Activity; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Cholecystokinin; Thiazoles | 1993 |